Customized Citrate Anticoagulation versus No Anticoagulant in Continuous Venovenous Hemofiltration in Critically ill patients with Acute Kidney Injury

Customized Citrate Anticoagulation vs. No Anticoagulant in Continuous Venovenous Hemofiltration in Critically ill patients with Acute Kidney Injury : a prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210924001

Enrollment

100

Registered

2021-09-24

Start date

2018-03-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Filter clotting in patients with acute kidney injury requiring continuous venovenous hemofiltration CVVH regional citrate anticoagulation customized citrate-based replacement fluid citrate accumulation bleeding

Interventions

Using customized citrate solution as anticoagulant and predilution replacement fluid during CVVH. ,Using no anticoagulant during CVVH

Experimental Procedure/Surgery,Active Comparator Procedure/Surgery

CVVH with Customized citrate anticoagulation,CVVH with No anticoagulant

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Age > 18 yours 2.Critically ill patients with acute kidney injury who admitted to ICU 3.Fullfils at least ONE of the following for initiating Continuous renal replacement therapy (CRRT) 3.1 Refractory volume overload 3.2 Refractory hyperkalemia 3.3 Uremic symptom 3.4 Refractory metabolic acidosis

Exclusion criteria

Exclusion criteria: 1.Patient who need systemic anticoagulation 2.Chronic renal replacement therapy 3.Pregnancy , Breast feeding 4.Post hepatic resection , severe acute liver failure , waiting list for liver transplantation 5.Serum Na > 160 mEq/L or Serum HCO3 > 40 mEq/L or pH >7.5 before renal replacement therapy 6.Active bleeding 7.Persistent symptomatic hypocalcemia or total calcium / ionized calcium ratio >2.5 8.Refuse to participate 9.Citrate allergy

Design outcomes

Primary

Measure	Time frame
the survival time of the first filter (1st circuit lifespan) until change filter or 72 hours continuous data (hour),the number of filters used within the first 72 hours continuous data	—

Secondary

Measure	Time frame
14-d Mortality 14 days categorical data,28-d Mortality 28 days categorical data,Renal recovery 28 days categorical data,Length of ICU stay until discharge from ICU continuous data,Adverse event 28 days categorical data	—

Countries

Thailand

Contacts

Public ContactRanistha Ratanarat

Faculty of Medicine Siriraj Hospital, Mahidol University

ranittha@hotmail.com0896685287

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026